Enrichment of full AAV capsids by preparative strong anion exchange chromatography
Biotechnology Progress · 2025
DOI: 10.1002/btpr.70065 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Progress, 2025. Verfasst von Suriyasri Subramanian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Purification Process Sciences, Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA. Hauptthemen laut MEDLINE: Dependovirus, Capsid, Genetic Vectors. Die Arbeit nennt 44 Literaturangaben. Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Recombinant adeno‐associated virus (rAAV) vectors are the leading in vivo gene delivery platform for the treatment of various human diseases. Scalable manufacturing of rAAV has been successfully demonstrated; however, the presence of non‐genome containing empty AAV capsids still remains a significant downstream bottleneck. Separation of empty and full rAAV vectors with linear gradient anion exchange chromatography is challenging to implement at large scale and often achieves only a low recovery of full rAAV capsids. Here we present a workflow to separate empty from full rAAV capsids using Capto Q™ resin with isocratic elution as an alternative. The workflow is based on a preliminary conductivity screening that identifies an optimal empty capsid removal salt concentration, followed by an isocratic two‐step elution method. This approach was successfully demonstrated with rAAV serotypes 8 and 9. Approximately 65% of full rAAV8 and rAAV9 capsids were recovered with an enrichment to greater than 80% and 90% full capsids, respectively. Process development using the same approach for rAAV6.2 proved to be more challenging and required a switch in elution salt and an increased concentration of MgCl 2 . The optimized two‐step purification protocol for AAV6.2 achieved the recovery of 68% of full capsids with a purity of greater than 80% full capsids.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Purification Process Sciences, Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
- Purification Process Sciences, Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
- Analytical Sciences, Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
- Downstream Bioprocessing R&D, Cytiva, Uppsala, Sweden.
ORCID-Profile: Suriyasri Subramanian
Förderung
- AstraZeneca
Zitieren
APA
Subramanian, S., Dembek, M., Auchus, N., Hines, A., Devine, P. W. A., Mcwhirter, Å. H., Maloisel, J. L., & Linke, T. (2025). Enrichment of full AAV capsids by preparative strong anion exchange chromatography. Biotechnology Progress. https://doi.org/10.1002/btpr.70065
Vancouver
Subramanian S, Dembek M, Auchus N, Hines A, Devine PWA, Mcwhirter ÅH, et al. Enrichment of full AAV capsids by preparative strong anion exchange chromatography. Biotechnology Progress. 2025. doi:10.1002/btpr.70065
BibTeX
@article{Subramanian2025,
author = {Subramanian, Suriyasri and Dembek, Marcin and Auchus, Nadia and Hines, Alistair and Devine, Paul W A and Mcwhirter, Åsa Hagner and Maloisel, Jean-Luc and Linke, Thomas},
title = {Enrichment of full AAV capsids by preparative strong anion exchange chromatography},
journal = {Biotechnology Progress},
year = {2025},
doi = {10.1002/btpr.70065}
}
EUVIMED